Teva Pharmaceutical Industries (TEVA) Cash from Operations (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Cash from Operations for 18 consecutive years, with 40000000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Operations rose 61.9% year-over-year to 40000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1714000000.0 (up 35.39% YoY) and the FY2025 annual result came in at 1649000000.0, up 32.24% from the prior year.
• Cash from Operations retreated to 40000000.0 in Q1 2026 per TEVA's latest filing, from 1158000000.0 in the prior quarter.
• Over the last five years, Cash from Operations for TEVA reached as high as 1184000000.0 in Q4 2023 and fell as low as 145000000.0 in Q1 2023.
• A 5-year average of 342000000.0 and a median of 227000000.0 in 2025 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2023 — Cash from Operations slumped 195.92% — and 2024, when it jumped 13760.0%.
• Year by year, Cash from Operations stood at 973000000.0 in 2022, then grew by 21.69% to 1184000000.0 in 2023, then tumbled by 51.44% to 575000000.0 in 2024, then soared by 101.39% to 1158000000.0 in 2025, then sank by 103.45% to 40000000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 40000000.0, 1158000000.0, and 369000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.